Radical sinus surgery may beat standard for tough nasal polyps
NCT ID NCT04852562
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compared two types of sinus surgery for people with chronic sinusitis and nasal polyps that involve a type of inflammation called eosinophilic. One surgery (MRESS) removes more tissue, including the middle turbinate, while the standard surgery (FESS) preserves it. The goal was to see if the more radical approach improves quality of life and reduces the need for repeat surgery. 110 Chinese patients were followed for a year after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- modified radical endoscopic sinus surgery (MRESS)
- What this could lead to
- If MRESS proves better, it could offer a more effective surgical option for people with stubborn nasal polyps, reducing symptoms and the need for repeat surgery.
- What could go wrong
- This is a small, single-center study (110 patients) with no blinding. Results may not apply to all patients, and more radical surgery carries higher risks like bleeding or scarring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
110 people
The number who actually took part.
- Started
-
Dec 2020
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * CRSwNP is diagnosed according to EPOS clinical guidelines and met surgical requirements, the blood eosinophil count was greater than 0.22; * Subjects/legal authorized representatives must understand the purpose and procedures of the study and voluntarily sign the informed consent, voluntarily participate in the study and comply with the study regulations, understand and comply with follow-up plan, and can correctly record the scale score, the administration frequency, accompanying drug use and adverse events, etc; * The examinee must be 18-65 years old, male or non pregnant female, limited to Chinese; * During the treatment and follow-up period, female subjects have no pregnancy and lactation plans; * The subjects did not participate in other clinical trials in the past three months and agreed not to participate in other clinical trials before reaching the end point of this trial; * Patients accompanying asthma must use their regular asthma treatment steadily in the past 6 weeks; Exclusion Criteria: * Women must not be pregnant, or breast-feeding; * Subjects with cystic fibrosis, congenital ciliary dyskinesia, fungal sinusitis, systemic vasculitis and granulomatous disease, tumor, and immunodeficiency are exclued; * Subjects accpted nasal endoscopic surgery within 6 months are exclued; * Subjects with an upper respiratory tract infection within 4 weeks of entering the study are excluded; * Subjects with serious metabolic, cardiovascular, autoimmune, neurology, blood, digestive, cerebrovascular, or respiratory system disease, or any disease interfering with the evaluation of results or affecting subjects safety are excluded, such as glaucoma and tuberculosis; * Currently participating in other clinical studies or in other clinical investigators within 30 days, or staff directly involved in this study; * Subjects with emotional or mental problems are excluded; * Subjects must not have received immunotherapy within the previous 3 months; * Subjects unsuitable for inclusion based on judgement of researchers are excluded;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic sinusitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sinus surgery without opioids: can dexmedetomidine do the job?
- Can a new anesthetic give surgeons a clearer view during sinus surgery?
- Can a new drug shrink nasal polyps and restore smell?
- Can a new drug shrink nasal polyps and restore smell?
- Can knowing frontal sinus anatomy make surgery safer?
- Can a drug that calms inflammation ease chronic sinusitis?